BGPT: Paper Review: Metabolic regulation of RNA methylation by the m6A-reader IGF2BP3

Explore by Goal

Quick Explanation Copied

Core claim: IGF2BP3 (an m6A reader) reprograms leukemia metabolism—especially glycolysis and one‑carbon metabolism—raising SAM availability and thereby increasing RNA m6A.

Long Explanation

Paper Review (Critical): Metabolic regulation of RNA methylation by the m6A-reader IGF2BP3

Preprint/record:

1) The proposed mechanistic chain (what the paper says)

IGF2BP3 supports glycolytic flux (Seahorse ECAR/lactate efflux; GC/MS steady-state pyruvate/lactate; glucose-to-metabolite enrichment decreases on IGF2BP3 loss), while OCR/TCA changes are largely not observed in the tested settings.
IGF2BP3 supports one-carbon metabolism and SAM production, with LC/MS showing reductions in serine/glycine-pathway metabolites and a significant change in SAM abundance and its glucose-derived incorporation when IGF2BP3 is depleted.
IGF2BP3 loss decreases bulk RNA m6A (ELISA/dot blot), while measured abundance and/or measured activity of core m6A writers/erasers (METTL3/14/16; FTO; etc.) is reported as unchanged.
Translation-level regulation of MAT2B: RNA-seq changes are reported as modest, global translation is unchanged by SUnSET, and polysome profiling shows reduced MAT2B mRNA polyribosome association upon IGF2BP3 depletion; MAT2A protein is reduced, consistent with reduced MAT2B stabilizing MAT2A.
In vivo and pharmacology support: IGF2BP3 depletion in transplanted tumors reduces RNA m6A; an IGF2BP3 inhibitor (I3IN-002) reduces ECAR/lactate efflux and RNA m6A in vitro and reduces RNA m6A in vivo (Lin-MLL-Af4 tumors and a PDX).

Important scope note (epitranscriptome coverage)

The study repeatedly uses bulk/total RNA m6A detection (ELISA, dot blots) rather than direct per-transcript m6A mapping (e.g., site-resolution sequencing). That means the chain is supported at the level of global m6A abundance, but the paper does not explicitly prove which transcripts lose methylation, nor whether MAT2B’s m6A pattern changes.

2) Evidence table (what assays support which links)

Mechanistic link	Assays used (from paper)	Strength in paper text	Main uncertainty / gap
IGF2BP3 → glycolysis	Seahorse XF (lactate efflux/ECAR), GC/MS steady-state pyruvate/lactate, glucose-13C labeling into glycolytic metabolites; respirometry/OCR/TCA analysis as orthogonal checks.	Moderate: multiple orthogonal metabolic readouts; some orthogonal negative findings (OCR/TCA) reported.	Still indirect for mechanism: e.g., which IGF2BP3 targets causally drive glycolytic flux?
IGF2BP3 → one-carbon metabolism → SAM	LC/MS metabolomics (serine/glycine/glutathione/cystathionine family); isotopologue patterns from labeled glucose into SAM.	Moderate: convergent metabolite directions + labeling into SAM.	Metabolic networks are highly redundant—lower SAM could be downstream of other changes (e.g., energy demand, stress), even if OCR/TCA are unchanged.
SAM availability → bulk RNA m6A changes	ELISA and dot-blots for RNA m6A; reported unchanged m6A writer/eraser activity/protein levels; inhibitor experiments showing attenuated additivity with METTL3 inhibition and MAT2A inhibition.	Moderate: mechanistic inference from inhibitor non-additivity.	Activity assays are typically lysate-based/indirect; without substrate-specific m6A flux measurements, SAM↔m6A causality remains partially inferred.
IGF2BP3 → translational control of MAT2B/MAT2A stability	Polysome profiling (MAT2B shift), protein expression shifts (MAT2B down; MAT2A down), cycloheximide chase consistent with MAT2A instability; independent literature support that MAT2B stabilizes MAT2A.	Moderate to strong: internal consistency + external stabilization literature.	The direct link “IGF2BP3 binds MAT2B mRNA” is supported by eCLIP, but the paper text provided does not show mutation-based dissection proving MAT2B 3’UTR binding is sufficient.

3) Critical appraisal (what’s strong vs what’s missing)

Strengths (multiple independent modalities)

Multi-omic convergence: metabolic profiling (Seahorse + GC/MS + LC/MS) converges on glycolysis/OCM deficits, and these correlate with bulk RNA m6A changes measured independently by ELISA and dot blots.
Mechanistic intermediate: the pathway is anchored to MAT2B translation and MAT2A stability, using polysome profiling and CHX chase logic, and supported by prior biochemical evidence that MAT2B stabilizes MAT2A.

Weaknesses / gaps (what could be wrong)

Bulk m6A readouts: total RNA ELISA/dot blot can miss transcript-specific effects and can confound changes with altered RNA abundance or distribution. The paper text claims equivalent RNA input (methylene blue staining), but site-resolution causality is not established.
Inferred causality from SAM: SAM reduction is compatible with reduced m6A deposition, but the paper relies on activity/inhibitor logic. Without direct measurement of methylation flux or METTL3/14 kinetics under matched SAM conditions, the direction “SAM limiting” remains partly inferred.
Alternative mechanisms for glycolysis/OCM shifts: IGF2BP3 loss may affect multiple RNAs and could indirectly change nutrient uptake, stress responses, or mitochondrial coupling. OCR/TCA stability is reported, but metabolism is complex and can be re-routed without large TCA shifts.
In vivo / inhibitor evidence strength in the provided text: the inhibitor I3IN-002 is mentioned as manuscript-under-review and “lab synthesized”; the mechanistic specificity and off-target risk cannot be fully assessed from the excerpt provided.

4) Context: how this fits into known m6A biology (skeptical integration)

Established base (writers/erasers/readers & m6A function)

m6A is a major RNA modification with regulatory roles in translation and gene expression.
m6A distribution in mRNAs is frequently enriched in 3’ UTRs near stop codons, aligning with roles mediated by RNA-binding proteins.
IGF2BP family proteins are implicated as m6A readers that affect RNA stability/translation in multiple contexts.

Synthesis critique: “metabolism ↔ epitranscriptome mutual regulation”

The paper’s key novelty is to connect IGF2BP3 function to cellular metabolite availability (SAM) and thereby to RNA methylation magnitude. This direction is consistent with broader literature that one-carbon metabolism supports methylation chemistry, and that SAM availability can influence methylation marks.

5) Bias & conflict-of-interest check (science-only)

Stated conflicts: the document states a consultant relationship of an author with AbbVie and that authors are inventors on a patent application including I3IN-002. This does not invalidate data, but it does motivate extra skepticism about specificity of inhibitor-related claims and about whether alternative explanations were exhaustively tested.

Pragmatic falsification targets (what would most strongly disprove the chain)

Show that IGF2BP3 perturbation does not change SAM or bulk RNA m6A under matched metabolic conditions.
Show that MAT2B is not causally downstream (e.g., MAT2B rescue that restores SAM/m6A without IGF2BP3, or MAT2B loss that abolishes IGF2BP3 rescue).

6) “What BGPT can do next” (bespoke routes)

Author reviews (click to read BGPT critiques)

Note: one author name in the provided text appears as “E S Lyna” and one as “Kabbani” (first name not given in the excerpt), so the author-review link uses the available name string.

Feedback:

Updated: March 26, 2026